Susquehanna International Group LLP Invests $68,000 in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)
Susquehanna International Group LLP acquired a new position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,144 shares of the company’s stock, valued at approximately $68,000.
Other large investors also recently bought and sold shares of the company. State Street Corp purchased a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter worth $129,000. Dimensional Fund Advisors LP bought a new stake in Milestone Pharmaceuticals during the fourth quarter valued at about $150,000. Squarepoint Ops LLC bought a new stake in Milestone Pharmaceuticals during the fourth quarter valued at about $158,000. Renaissance Technologies LLC raised its holdings in Milestone Pharmaceuticals by 986.1% during the fourth quarter. Renaissance Technologies LLC now owns 164,000 shares of the company’s stock valued at $1,099,000 after acquiring an additional 148,900 shares during the period. Finally, Pura Vida Investments LLC raised its holdings in Milestone Pharmaceuticals by 350.0% during the fourth quarter. Pura Vida Investments LLC now owns 450,000 shares of the company’s stock valued at $3,015,000 after acquiring an additional 350,000 shares during the period. Hedge funds and other institutional investors own 51.88% of the company’s stock.
A number of equities research analysts have commented on MIST shares. HC Wainwright started coverage on Milestone Pharmaceuticals in a report on Thursday, March 11th. They set a “buy” rating and a $20.00 price target on the stock. Zacks Investment Research raised Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 3rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Milestone Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $13.50.
Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Sunday, March 28th. The company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.28. As a group, research analysts forecast that Milestone Pharmaceuticals Inc. will post -1.99 EPS for the current fiscal year.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications.
Want to see what other hedge funds are holding MIST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Milestone Pharmaceuticals Inc. (NASDAQ:MIST).
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.